Velpatasvir, also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in HCV replicon assays. GS-5816 demonstrated pangenotypic antiviral activity in patients with genotype 1-4 HCV infection. It will be further evaluated in combination with other pangenotypic direct-acting antivirals to achieve the goal of developing a well-tolerated, highly effective treatment for all HCV genotypes.
Reference: Reddy, Bandi Parthasaradhi; Reddy, Kura Rathnakar; Narasingam, Mogili; Krishna, Bandi Vamsi. Process for the preparation of velpatasvir. Assignee Hetero Research Foundation, India. IN 201641022433. (2018).
Reddy, Bandi Parthasaradhi; Reddy, Kura Rathnakar; Narasingam, Mogili; Krishna, Bandi Vamsi. Process for the preparation of velpatasvir. Assignee Hetero Research Foundation, India. IN 201641022433. (2018).
Fu, Shaojun; Huang, Chengjun; Ren, Yi; Cai, Huirong; Wang, Qiong; Yang, Xin'an; Li, Wei. Preparation of velpatasvir and its derivative. Assignee Shanghai ForeFront Pharmceutical Co., Ltd., Peop. Rep. China. WO 2018153380. (2018)
Wang, Jianming. Preparation of amino acid derivatives as anti-hepatitis C virus agents. Assignee Beijing Meibeita Pharmaceutical Research Co., Ltd., Peop. Rep. China. CN 107540679. (2018).
